MARKETS / NASDAQ / NTRA
NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP

Natera, Inc. NTRA

13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.3B
▲ 35.9% vs FY2024
EPS · FY25
$-1.52
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-14.3%
Net margin · FY25
-9.0%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.3B
Revenue, FY2025 · full 13-year series below
Revenue Net income
0.81.62.42.3-0.220132016201920222025
0.81.62.42.3-0.22016201920222025

The company lost 9 cents on every revenue dollar this year.

Per share
USD -1.52
Diluted EPS, FY2025
EPS
0.40.81.2-1.5220132016201920222025
0.40.81.2-1.522016201920222025

The company pays no cash dividend.

Profitability
-14.3%
Return on equity, FY2025
ROE
0.250.50.751-14.3%20132016201920222025
0.250.50.751-14.3%2016201920222025
Operating margin-13.4%
Net margin-9.0%
Return on assets-10.3%

Each USD of equity lost 14 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+42.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+41.1%
+42.6%
+28.3%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.14B
Shares outstanding, FY2025
0.010.1420132016201920222025
0.050.142016201920222025
Change, 5 years+62.0%
Change, 10 years+177.5%

The share count grew 62% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.4B
total assets, end of FY2025
Total assetsUSD 2.4B
EquityUSD 1.7B
CashUSD 1.1B
Gross debtUSD 80.3M
Net debtUSD -995.8M
Current ratio3.39×

The company holds more cash than debt.

History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
2.3
1.7
1.1
0.8
0.6
0.4
0.3
0.3
0.2
0.2
0.2
0.2
0.1
Operating income $B
−0.3
−0.2
−0.4
−0.5
−0.5
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
EBITDA $B
−0.3
−0.2
−0.4
−0.5
−0.5
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
Income tax $B
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
·
Net income $B
−0.2
−0.2
−0.4
−0.5
−0.5
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−1.52
−1.53
−3.78
−5.57
−5.21
−2.84
−1.79
−2.22
−2.59
−1.95
−2.68
−1.07
−9.66
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−14.3
−19.4
−59.1
−80.6
−82.8
−60.1
−80.3
−445.1
−162.9
−54.2
−255.1
·
·
Shares out B
0.14
0.13
0.12
0.11
0.10
0.09
0.08
0.06
0.05
0.05
0.05
0.01
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed